In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.
Hypothesis: COVID-19+ hospitalized patients with preexisting CVD or newly onset CVD at time of hospitalization have different clinical outcomes compared to those without CVD and COVID-19+. Objectives: The primary aim of this study is to gather observational data, starting from February 1st 2020 until the end of the pandemic, to compare clinical outcomes COVID+ hospitalized patients at HUG or in a care center in Geneva with pre-existing or newly onset CVD, to COVID+ hospitalized patients at HUG or in a care center in Geneva without pre-existing CVD. The secondary aims of this study are: * To determine the association between COVID-19 disease and CVD, based on: age, previous CV diseases, CV risks factors, CV medications (e.g. ACE Inhibitors or angiotensin II receptor antagonists) * To explore CVD profiles that may influence COVID-19 disease outcomes * To determine the cause of death in CVD patients (either with preexisting CVD or newly diagnosed with CVD) * To understand the vulnerability of the myocardium (new event of either heart failure, acute coronary syndrome, arrhythmia, myocarditis) in patients with COVID-19 disease.
Study Type
OBSERVATIONAL
Enrollment
1,927
all the patients hospitalized in Geneva and SARS-Cov2 positive
Geneva University Hospital (HUG)
Geneva, Switzerland
mobidity discharge
To compare morbidity during hospital stay in COVID-19+ patients with or without preexisting CVD.
Time frame: 0 days after hospitalization
mobidity at 30 days
To compare morbidity 30 days after hospitalization in COVID-19+ patients with or without preexisting CVD.
Time frame: 30 days after hospitalization
mobidity 1 year after hospitalization
To compare morbidity 1 year after hospitalization stay in COVID-19+ patients with or without preexisting CVD.
Time frame: 1 year after hospitalization
mortality discharge
To compare mortality during hospital stay in COVID-19+ patients with or without preexisting CVD.
Time frame: 0 days after hospitalization
mortality 30 days after hospitalization
To comparemortality30 days after hospital stay in COVID-19+ patients with or without preexisting CVD.
Time frame: 30 days after hospitalization
mortality 1 year after hospitalization
To compare mortality 1 year after hospital stay in COVID-19+ patients with or without preexisting CVD.
Time frame: 1 year after hospitalization
Clinical outcomes according to medication at admission
Clinical outcomes according to medication at admission evaluated at hospital discharge
Time frame: 0 days after hospitalization
Clinical outcomes according to medication at admission
Clinical outcomes according to medication at admission evaluated 30 days after hospitalization
Time frame: 30 days after hospitalization
Clinical outcomes according to medication at admission
1 year after hospitalization
Time frame: 1 year after hospitalization
Clinical outcomes related to preexisting cardiovascular risk factors at admission
Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated after hospital discharge
Time frame: 0 days after hospitalization
Clinical outcomes related to preexisting cardiovascular risk factors at admission
Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 30 days after hospital discharge
Time frame: 30 days after hospitalization
Clinical outcomes related to preexisting cardiovascular risk factors at admission
Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 1 year after hospitalization
Time frame: 1 year after hospitalization
New onset of CVD induced by COVID-19 disease
New onset of CVD induced by COVID-19 disease at discharge
Time frame: 0 days after hospitalization
New onset of CVD induced by COVID-19 disease
New onset of CVD induced by COVID-19 disease evaluated 30 days after hospitalization
Time frame: 30 days after hospitalization
New onset of CVD induced by COVID-19 disease
New onset of CVD induced by COVID-19 disease at discharge evaluated 1 year after hospitalization
Time frame: 1 year after hospitalization
Cost of hospital stay
Cost of hospital stay
Time frame: 0 days after hospitalization
Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).
Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).
Time frame: 30 days after hospitalization
Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).
Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).
Time frame: 1 year after hospitalization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.